New whooping cough vaccine shows promise for toddlers

NCT ID NCT07213089

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a new booster vaccine called DTaPgen in 290 healthy toddlers aged 15 to 36 months. The goal was to see if it works as well as a currently licensed vaccine to protect against whooping cough, diphtheria, and tetanus. Children received a single shot, and researchers measured their immune response and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
DTaPgen vaccine (recombinant acellular pertussis combined with diphtheria and tetanus)
What this could lead to
If successful, this could provide a new booster option to protect young children against whooping cough, potentially with fewer side effects than current vaccines.
What could go wrong
This is a mid-stage trial with only 290 toddlers, so results may not apply to all children. The vaccine may not prove as effective or safe as the licensed version in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERTUSSIS (WHOOPING COUGH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kamphaengphet Hospital

    Kamphaeng Phet, Changwat Kamphaeng Phet, 62000, Thailand

  • Phaholpolpayuhasena Hospital

    Kanchanaburi, Kanchanaburi, 71000, Thailand

  • Vaccine Trial Centre (VTC), Faculty of Tropical Medicine, Mahidol University

    Bangkok, Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.